Jeremy Gleeson, MD
Endocrinology, Diabetes & Metabolism · Albuquerque, NMNPI 1215960893
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 49.4% of the total. Reporting peaked in 2019 at $29,550 and has fallen 86.9% since, to $3,856 in 2025. Among endocrinology, diabetes & metabolism clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $392.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$23K
- Kyowa Kirin, Inc.$5K
- Genentech USA, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$3K
- Baxter Healthcare$3K
- Sage Therapeutics, LLC$2K
- plus $8K from 17 others
Across 1 payment — averaging $350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$350
What the payments were for
- Consulting fees$15,71834%
- Speaking & faculty fees$15,36533%
- Travel & lodging$9,77521%
- Food & beverage$5,09111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 37 | $22,719 |
| Kyowa Kirin, Inc. | 17 | $4,594 |
| Genentech USA, Inc. | 7 | $3,324 |
| Otsuka America Pharmaceutical, Inc. | 2 | $2,800 |
| Baxter Healthcare | 3 | $2,800 |
| Sage Therapeutics, LLC | 1 | $1,800 |
| Novartis | 1 | $1,668 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,650 |
| Sanofi-aventis U.S. LLC | 5 | $699 |
| Insulet Corporation | 12 | $572 |
| Azurity Pharmaceuticals, Inc. | 3 | $570 |
| Lilly USA, LLC | 6 | $460 |
| Novo Nordisk | 4 | $442 |
| Dexcom, Inc. | 4 | $411 |
| Amgen(2 entities) | 3 | $386 |
| Boehringer Ingelheim | 3 | $309 |
| Abbott | 2 | $234 |
| Radius Health, Inc. | 1 | $122 |
| Sanofi | 1 | $105 |
| Medtronic | 1 | $100 |
| Bayer | 1 | $81 |
| Tandem Diabetes Care, Inc. | 1 | $54 |
| Mannkind Corporation | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DASOTRALINE$12,506
- SEP-856$6,253
- NOURIANZ$4,082
- XOLAIR$3,166
- ELIQUIS$1,650
- KYNMOBI$1,600
- SOLIQUA 100/33$694
- Omnipod$251
- FREESTYLE LIBRE 3$234
- JARDIANCE$230
- DEXCOM G7 GSS (161)$213
- Prolia$175
- Wegovy$123
- Tymlos$122
- Ozempic$121
- TOUJEO$115
- TEPEZZA$113
- MOUNJARO$113
- DEXCOM STELO GLUCOSE BIOSENSOR$107
How this compares
$45,948 in reported general payments places this provider in the 95th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $324,701 |
| TrulicityDulaglutide | 110 | $159,041 |
| JardianceEmpagliflozin | 134 | $115,612 |
| MounjaroTirzepatide | 58 | $68,098 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $42,275 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $37,591 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $35,411 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 163 | $27,315 |
| JanuviaSitagliptin Phosphate | 21 | $25,940 |
| Testosterone | 89 | $22,939 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,948 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $20,170 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $19,993 |
| Novolog FlexpenInsulin Aspart | 65 | $18,770 |
| FarxigaDapagliflozin Propanediol | 14 | $18,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $442 | $332,943267 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N | $460 | $241,437221 claims |
| Boehringer IngelheimJardiance, Glyxambi | $309 | $122,750146 claims |
| Sanofi-aventis U.S. LLCLantus | $699 | $5,59729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Albuquerque
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Namrata JannareddyAlbuquerque$4K
- Anita Sloan-GarciaAlbuquerque$4K
- Lisa EreifejAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.